Real life treatment of Cholinergic Urticaria with Omalizumab

Publication date: Available online 9 October 2018

Source: Journal of Allergy and Clinical Immunology

Author(s): S. Altrichter, M. Chuamanochan, H. Knoth, A. Asady, T. Ohanyan, M. Metz, M. Maurer

Abstract

Background

Cholinergic urticaria (CholU), a frequent type of chronic inducible urticaria, presents with small itchy wheals upon physical exercise or passive warming. Omalizumab has been shown to be very effective in patients with chronic spontaneous urticaria. Whether or not omalizumab is also effective in CholU is largely unknown.

Aim

To assess the effectiveness of omalizumab treatment in CholU

Method

We assessed the effects of real life omalizumab treatment at standard and higher than standard doses in CholU patients including their time to response, the effects on concomitant urticaria forms and links to clinical features.

Results

Of 16 CholU patients treated with omalizumab, 11 (68%) reported a major or complete response, 2 patients reported a minor effect (13 %) and 3 patients (19%) showed no benefit. Omalizumab updosing led to complete response in 4 of 6 patients, who did not achieve controlled disease on standard dosed omalizumab therapy, i.e. 300 mg/4wks. Time to onset of benefit was fast, and concomitant urticaria forms showed similar response patterns. Treatment effects were linked to patient gender, with better responses in female patients (p < 0.05), but not patient age, age at onset of disease, duration of disease, or total IgE serum levels.

Conclusion

Omalizumab treatment is effective in the majority of CholU patients, especially in female patients. Most non-responders to standard-dosed omalizumab benefit from updosing. Our findings call for controlled clinical trials of omalizumab and other IgE-targeted treatments in CholU.

https://ift.tt/2E9dI0Q